Ad Scientiam is a medical technology company, that offers digital biomarkers which collects physiological and behavioral data. It provides mobile application which monitors patients' behaviors and sharers the data to healthcare professionals. Ad Scientiam serves individuals, healthcare professionals and pharmaceutical companies. The company's solution finds application in the areas of Parkinson disease, Asthma, Atopic Dermatisi, Insomnia, Multiple Sclerosis, Oncology and Alzheimer's disease among others. It also operates an office in the US. Ad Scientiam is headquartered in Paris, Ile de France, France.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Ad Scientiam
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Ad Scientiam Company Overview
- Ad Scientiam Company Snapshot
- Ad Scientiam Pipeline Products and Ongoing Clinical Trials Overview
- Ad Scientiam - Pipeline Analysis Overview
- Ad Scientiam - Key Facts
- Ad Scientiam - Major Products and Services
- Ad Scientiam Pipeline Products by Development Stage
- Ad Scientiam Ongoing Clinical Trials by Trial Status
- Ad Scientiam Pipeline Products Overview
- Actisleep
- Actisleep Product Overview
- CARDICARE
- CARDICARE Product Overview
- Major Depressive Disorder Mobile App
- Major Depressive Disorder Mobile App Product Overview
- Major Depressive Disorder Mobile App Clinical Trial
- Mobile Application - Alzheimer’s
- Mobile Application - Alzheimer’s Product Overview
- Mobile Application - Asthma
- Mobile Application - Asthma Product Overview
- Mobile Application - Insomnia
- Mobile Application - Insomnia Product Overview
- Mobile Application - Oncology
- Mobile Application - Oncology Product Overview
- Mobile Application - Parkinson’s
- Mobile Application - Parkinson’s Product Overview
- Mobile Application - Rheumatoid Arthritis
- Mobile Application - Rheumatoid Arthritis Product Overview
- Mobile Application - Schizophrenia
- Mobile Application - Schizophrenia Product Overview
- MSCopilot Mobile App
- MSCopilot Mobile App Product Overview
- OPTIS
- OPTIS Product Overview
- OPTIS Clinical Trial
- Ad Scientiam - Key Competitors
- Ad Scientiam - Key Employees
- Ad Scientiam - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Ad Scientiam, Recent Developments
- Oct 28, 2019: Ad Scientiam tracks valuable digital biomarkers for clinical research
- Jan 29, 2019: Ad Scientiam selected for Pfizer Acceleration Program
- Nov 14, 2018: Ad Scientiam announces clinical validation of its MSCopilot solution
- Nov 14, 2018: Ad Scientiam, a french startup hosted at the Brain & Spine Institute (paris), announces clinical validation of its MSCopilot solution
- Jul 18, 2018: MyHBP, application dedicated to the monitoring of benign prostatic hypertrophy
- Jul 18, 2018: TLM : new version of MSCopilot
- Jul 17, 2018: Ad Scientiam selected for EIT Health GoGlobal Canada Programme
- Jun 08, 2018: Altran accompanies Ad Scientiam on the European compliance of MSCopilot
- Jun 01, 2018: The 16 Health start-ups selected by Product Market Fit
- May 30, 2018: MSCopilot is evolving for World MS Day
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Ad Scientiam Pipeline Products and Ongoing Clinical Trials Overview
- Ad Scientiam Pipeline Products by Equipment Type
- Ad Scientiam Pipeline Products by Indication
- Ad Scientiam Ongoing Clinical Trials by Trial Status
- Ad Scientiam, Key Facts
- Ad Scientiam, Major Products and Services
- Ad Scientiam Number of Pipeline Products by Development Stage
- Ad Scientiam Pipeline Products Summary by Development Stage
- Ad Scientiam Ongoing Clinical Trials by Trial Status
- Ad Scientiam Ongoing Clinical Trials Summary
- Actisleep - Product Status
- Actisleep - Product Description
- CARDICARE - Product Status
- CARDICARE - Product Description
- Major Depressive Disorder Mobile App - Product Status
- Major Depressive Disorder Mobile App - Product Description
- Major Depressive Disorder Mobile App - Major Depressive Disorder: Early Prediction of Non-response to Antidepressant Therapy Via a Mobile Digital Scale
- Mobile Application - Alzheimer’s - Product Status
- Mobile Application - Alzheimer’s - Product Description
- Mobile Application - Asthma - Product Status
- Mobile Application - Asthma - Product Description
- Mobile Application - Insomnia - Product Status
- Mobile Application - Insomnia - Product Description
- Mobile Application - Oncology - Product Status
- Mobile Application - Oncology - Product Description
- Mobile Application - Parkinson’s - Product Status
- Mobile Application - Parkinson’s - Product Description
- Mobile Application - Rheumatoid Arthritis - Product Status
- Mobile Application - Rheumatoid Arthritis - Product Description
- Mobile Application - Schizophrenia - Product Status
- Mobile Application - Schizophrenia - Product Description
- MSCopilot Mobile App - Product Status
- MSCopilot Mobile App - Product Description
- OPTIS - Product Status
- OPTIS - Product Description
- OPTIS - Performance and Safety of a Digital Tool for Unsupervised Self-assessment of Neuromyelitis Optica Spectrum Disorder
- Ad Scientiam, Key Employees
- Ad Scientiam, Other Locations
- Glossary
- Ad Scientiam Pipeline Products by Equipment Type
- Ad Scientiam Pipeline Products by Development Stage
- Ad Scientiam Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Altrabio SAS
- Biocitech SAS
- Bionext SA
